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Introduction: Prognosis of Coronavirus disease 2019 (Covid-19) patients with vascular
risk factors, and certain comorbidities is worse. The impact of chronic neurological
disorders (CND) on prognosis is unclear. We evaluated if the presence of CND in Covid-19
patients is a predictor of a higher in-hospital mortality. As secondary endpoints, we
analyzed the association between CND, Covid-19 severity, and laboratory abnormalities
during admission.
Methods: Retrospective cohort study that included all the consecutive hospitalized
patients with confirmed Covid-19 disease from March 8th to April 11th, 2020. The
study setting was Hospital Clínico, tertiary academic hospital from Valladolid. CND was
defined as those neurological conditions causing permanent disability. We assessed
demography, clinical variables, Covid-19 severity, laboratory parameters and outcome.
The primary endpoint was in-hospital all-cause mortality, evaluated by multivariate
cox-regression log rank test. We analyzed the association between CND, covid-19
severity and laboratory abnormalities.
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Results: We included 576 patients, 43.3% female, aged 67.2 years in mean. CND were
present in 105 (18.3%) patients. Patients with CND were older, more disabled, had more
vascular risk factors and comorbidities and fewer clinical symptoms of Covid-19. They
presented 1.43 days earlier to the emergency department. Need of ventilation support
was similar. Presence of CND was an independent predictor of death (HR 2.129, 95%
CI: 1.382–3.280) but not a severer Covid-19 disease (OR: 1.75, 95% CI: 0.970–3.158).
Frequency of laboratory abnormalities was similar, except for procalcitonin and INR.
Conclusions: The presence of CND is an independent predictor of mortality in
hospitalized Covid-19 patients. That was not explained neither by a worse immune
response to Covid-19 nor by differences in the level of care received by patients
with CND.
Keywords: SARS-CoV-2, nervous system diseases, stroke, mortality, prognosis
INTRODUCTION
Hypertension, diabetes, cardiovascular disorders, pulmonary
disorders, and cancer have been associated with an increased risk
of severe Coronavirus disease 2019 (Covid-19) and mortality (1–
6). Since the first edition of the clinical management protocol
of Covid-19 with severe acute respiratory infection, the World
Health Organization (WHO) recommended that those patients,
even if they present with mild symptoms, should be admitted to
a designated unit for close monitoring (7).
The frequency, type and implications of neurological
comorbidity in Covid-19 patients is largely unexplored. A recent
review found a frequency ranging from 1.4 to 40%, with a pooled
percentage of having a pre-existing neurological disease of 8.0%
(8). The possible reasons for the heterogeneous results were the
varying definitions, the lack of specific studies and underreported
frequency. The impact of neurological comorbidities in Covid-
19 disease is yet unknown. Covid-19 patients requiring intensive
care unit (ICU) admission had prior history of cerebrovascular
disease more frequently (3), but in some series, cerebrovascular
disorders were classified together with cardiovascular disease
(9). The aim of this study was to evaluate if the presence of
comorbid chronic neurological disorders is associated with a
worse prognosis in patients with Covid-19 disease.
METHODS
Study Design
This study was done according to the registry of neurological
symptoms in Covid-19 patients of the Spanish Society of
Neurology and designed by the investigators. The study was done
according to the strengthening the reporting in observational
studies in epidemiology (STROBE) (10) statement. The study was
done in the Clinic University Hospital, tertiary public hospital
from Valladolid, Spain, free of charge for patients. Data were
collected, analyzed and interpreted by the authors. All the authors
reviewed and approved the final version of manuscript.
Data Sources
We collected data from the electronic medical records. The data
about the history prior to the admission was collected from
the admission report, emergency department (ED) history and
primary care electronic records. The local authorities created a
reference contact phone line, that followed patients with typical
Covid-19 symptoms daily or every other day. Regarding the
hospitalization period data, we gathered the medical records.
Patients were treated according to the national Covid-19
management protocol standard of care (SOC) (11). The study
period included all consecutive patients that were admitted to
the hospital with a Covid-19 confirmed diagnosis betweenMarch
8th and April 11th, 2020. The information was reviewed from
April 21st to May 1st. The source of the data was the admission
department and the department of microbiology records, whilst
notification of every Covid-19 positive was mandatory during the
time of the study.
Covid-19 Disease Diagnosis
Covid-19 diagnosis was based on real-time reverse-transcriptase-
polymerase-chain-reaction (RT-PCR) assay (LightMIx Modular
SARS-CoV (COVID19) E-gene and LightMIx Modular
SARS-CoV (COVID19) RdRP, Roche Diagnostics S.L.)
of oropharyngeal-nasopharyngeal swab, sputum or lower
respiratory tract sample; or was based on the presence of
anti-SARS-CoV-2 IgM+IgA antibodies (COVID-19 ELISA
IgM+IgA; Vircell, S.L. Granada, Spain) in serological test
in patients with clinical symptoms, according to the WHO
protocols (12). Patients without laboratory-confirmed diagnosis
were not included. Recruitment was probabilistic and all
consecutive patients were included. Only hospitalized patients
were included. Data was extracted according to a predefined
protocol by 13 neurologists that were involved in the treatment
of Covid-19 patients. The needed time to review it patient was
20–30 min.
Chronic Neurological Disorders Definition
We used the WHO definition of disabling chronic neurological
disorders (CND), as those neurological disorders that (a) caused
persistent disability, (b) limited the individual’s functioning,
and (c) interfered with the person’s ability to engage in
activities (13). We included conditions affecting both mental and
physical function. CND included dementia, movement disorders,
prior stroke with long-term sequelae, neuromuscular disorders,
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spinal disorders, symptomatic central nervous system cancer,
chronic encephalopathies or neuro-inflammatory disorders. (Full
definitions in Supplementary Material). Researchers specifically
assessed the presence of prior history of neurological diseases
and only those conditions fulfilling (a), (b), and (c) criteria
were included.
Variables
We analyzed demographic variables, prior medical history,
clinical presentation, the course of the disease and treatment.
Demographic variables included age, sex, date of symptoms
onset. Regarding comorbidities, we analyzed the presence of
hypertension (systemic blood pressure higher than 140/90
mmHg in two prior determinations), diabetes (fasting blood
glucose >126 mg/dl on two separate tests, HbA1c > 6,5%,
blood glucose level >200mg after oral glucose overload or blood
glucose level >200 mg/dl with diabetes symptoms), smoking
habit (current or in the preceding 6 months), cardiovascular
diseases (coronary artery disease, congenital heart diseases,
cardiomyopathies, arrythmias, valvular heart disease, aortic
aneurysms, and peripheral artery disease), chronic respiratory
diseases (chronic obstructive pulmonary disease (COPD),
asthma, occupational lung diseases, interstitial lung diseases and
pulmonary hypertension), cancer (excluding epidermoid and
basal cell carcinoma), immunocompromised state (congenital
or acquired). We specifically evaluated the presence of CND.
We analyzed baseline performance status by using the modified
Ranking scale (mRS), ranging from 0 (no symptoms) to 6 (dead),
being defined 3 as the presence of moderate disability and need
of assistance (14).
Concerning the clinical presentation, we evaluated if the
source of contagion was suspected or not, the time between
the first symptom and the emergency department (ED)
presentation. We analyzed the general symptoms, including
fever (defined as axillary temperature equal or higher than
37.5%), asthenia, cough, cutaneous rash, dyspnea, diarrhea, chest
pain, expectoration, headache, myalgia, nausea, odynophagia,
rhinorrhea, and vomiting. We describe the type of Covid-
19 diagnosis, either by RT-PCR or serological tests. We
analyzed the frequency of abnormal chest imaging, either by
X-ray or Computerized Tomography (CT). We evaluated the
laboratory results on admission and the worst values during
the hospitalization. The analyzed parameters were leukocytes
[cell count × 109 / L, reference value (RV):4–10], lymphocytes
(count× 109/L, RV: 0.9–5.2), platelets (count× 109 /L, RV: 150–
400), hemoglobin (g/dL, RV: 12–16), international normalized
ratio (INR, RV: 0.8–1.3), D-dimer (ng/dL, RV: <500), lactate
dehydrogenase (U/L, RV: 135–250), creatine-kinase (U/L, RV:
20–170), glomerular filtration rate corrected by body area
(ml/min/1.73 m2, RV > 90), C-reactive protein (mg/L, RV: 1–5),
procalcitonin (ng/mL, RV:<5), interleukine-6 (pg/mL, RV<5.9),
ferritin (ng/mL, RV: 15–150). Interleukine-6 and ferritin were not
available on admission. We evaluated the percentage of patients
that presented abnormal results on admission and during
the hospitalization. We describe the received treatment, that
according to the local SOC, being the possible drug dose regimes
hydroxychloroquine 400mg bid for 5 days, lopinavir/ritonavir
400/100mg bid, methylprednisolone 250mg three consecutive
days and interferon beta-1b (11). We also report the need of
oxygen therapy, the use of mechanical ventilation, the need of
Intensive Care Unit (ICU) admission and the all-cause mortality.
The severity of the Covid-19 disease was defined according to the
American Thoracic Society guidelines for community-acquired
pneumonia (15) (Supplementary Material). We defined severe
Covid-19 disease as the presence of either severe pneumonia or
acute respiratory distress syndrome (ARDS) (16).
Study Endpoints
The primary endpoint was in-hospital mortality of Covid-19 in
patients with CND, calculated by multivariate regression and
survival probability by Cox regression, adjusted by the possible
confounders and effect modifiers. As secondary endpoints, we
aimed to analyze the Covid-19 severity in CND patients and the
presence of Covid-19 related laboratory abnormalities.
Statistical Analysis
Qualitative and ordinal variables are expressed as frequency
and percentage. Continuous variables are presented as medians,
interquartile range (IQR), and minimum-maximum value or
mean and standard deviation (SD). Missing data was managed
by complete case analysis. In the statistical analysis we employed
Chi2 test or Fisher’s Exact test for the contrast of categorical
variables, adjusting p-value by Bonferroni method for multiple
comparisons correction. We employed Student T-test for the
contrast of categorical and continuous variables. The level of
significance threshold was set in 0.05, after adequate adjustment.
Due to the exploratory nature of the study, we did not calculate
sample size.
For the primary endpoint, we conducted a univariate
regression analysis of all baseline variables and all the variables
that showed statistical association with higher odds of death and
a p-value lower or equal than 0.1, were included in a multivariate
regression analysis. All CND were analyzed together. We present
the odds ratio (OR) and the 95% confidence interval (CI).
Survival probability over time was assessed by Cox-regression
analysis with hazard ratio (HR) and the corresponding 95% CI
analysis, adjusted by all the covariates that were significant in
the univariate regression analysis. Differences in Kaplan Meier
Curves were analyzed by the log-rank test.
For the secondary endpoint severe-Covid-19 disease, we
repeated the same analysis as for the primary endpoint. To
evaluate if laboratory parameters were more often abnormal in
patients with CND, we created a regression analysis adjusting
for age, mRS and sex. Statistical analysis was performed with
SPSS v.26 (IBM Corp. Armonk, NY) by DGA. All datasheets are
available for other researchers under reasonable request.
Ethical Aspects
The study protocol was approved by the institutional review
board of Valladolid Este health area (PI-20-1751). Written
informed consent was waived given the risk of contagion and the
urgent need of data.
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Data Availability
Datasheets are available for other researchers under
reasonable request.
RESULTS
During the study period, 580 consecutive patients were admitted
and hospitalized to our hospital with a positive test for SARS-
CoV-2, being excluded four of them. Supplementary Figure 1
shows the flow diagram of patients. The sample included thus
576 patients, 250 (43.3%) female, with a mean age of 67.2
(sd:14.7), ranging from 23 to 98 years. One hundred and
five (18.3%) patients had one or more chronic neurological
disorders (CND). The frequency of specific disorders was
40 (6.9%) patients with cerebrovascular disease, 32 (5.5%)
patients with cognitive disorders, 24 (4.1%) patients with
neuromuscular and spinal diseases, 16 (2.7%) patients with
movement disorders, four (0.7%) patients with symptomatic
central nervous system tumors, two (0.3%) patients with multiple
sclerosis and isolated cases of Neurobehçet disease, neurolupus
and one malformation syndrome. The full list of patients
is available in Supplementary Materials. Patients with CND
were older, more disabled at baseline and had hypertension
and diabetes more often. Table 1 shows demographic variables,
vascular risk factors frequency and comorbidities.
The source of the contagion was suspected in 282 (49%) of
all cases, without differences between patients with CND (58
(55.2%) cases) and the rest of the patients (224 (47.6%) cases).
















74.97 (12.69) 65.45 (14.63) <0.001†
Female sex 250
(43.4%
50 (47.6%) 200 (42.5%) 0.384‡
Hypertension 300
(52.1%)
75 (71.4%) 225 (47.8%) <0.001‡
Diabetes 113
(19.6%)
34 (32.4%) 79 (16.8%) 0.001‡
Smoking habit 118
(20.5%)
22 (21.0%) 96 (20.4%) 0.894‡
Cardiac disease 154
(26.7%)
41 (39.0%) 113 (24.0%) 0.002‡
Respiratory disease 145
(25.2%)
31 (29.5%) 114 (24.2%) 0.264‡
Cancer 94
(16.3%)
22 (21.0%) 72 (15.3%) 0.188‡
Immunodepression 32 (5.6%) 10 (0.5%) 22 (4.7%) 0.059‡
Mean mRS 0.61
(1.12)
1.73 (1.48) 0.36 (0.84) <0.001†
mRS, Modified Rankin Scale; †Student T-Test; ‡Two-sided Fisher’s Exact test.
The most frequent symptoms on presentation were fever and
cough. Patients with CND had less frequently cough, asthenia,
diarrhea, myalgia, chest pain, headache or lightheadedness. The
frequency and type of general presenting symptoms is shown in
Supplementary Table 3.
Latency Between Symptom Onset and ED
Presentation
The mean time between symptom onset and ED visit in
patients with neurological comorbidities was 5.27 (sd: 7.72)
days, compared with 7.81 (sd: 5.66) days in those without prior
neurological history. After adjusting for age, mRS, sex, vascular
risk factors and comorbidities, linear regression analysis was
significant (B coefficient −1.436, 95% CI: −2.844- −0.28, p =
0.046). Figure 1 shows the interval between symptom onset and
ED visit in patients with and without neurological comorbidities
in patients with and without CND.
Diagnosis and Management of Patients
Diagnosis was confirmed by RT-PCR in 546 (94.8%) of
cases and/or serology in 175 (30.4%). Chest imaging was
abnormal in 549 patients (95.3%). Patients with CND
received hydroxychloroquine (83.8 vs. 92.6%, p = 0.008) and
lopinavir/ritonavir (81.9 vs. 92.1%, p = 0.003) less frequently.
Frequency of methylprednisolone or interferon use was similar.
Need of oxygen therapy was more frequent in CND patients
(83.8 vs. 66.2%, p = 0.001). Frequency of ventilatory support or
ICU admission was similar.
Course of the Disease
Concerning the clinical course, 393 (68.2%) of patients had a
severe pneumonia or ADRS and 127 (22.0%) died. Nine patients
had not pneumonia but had severe illness because of septic shock
5 (0.8%), pulmonary embolism without pneumonia 2 (0.3%), and
one case (0.1%) of lithium intoxication and one case (0.1%) of
fatal gastrointestinal bleed. Patients with CND had non-severe
pneumonia less frequently (12.4 vs. 27.4%, p= 0.002) and ADRS
more frequently (30.5 vs. 19.6%, p = 0.020). Mortality of CNS
patients was 44.8%, compared with 17% in the rest of the sample
(p < 0.001). Supplementary Table 4 describes treatment and
severity of Covid-19 disease.
Primary Endpoint: Predictors of Mortality
In the univariate regression analysis, baseline disability, age,
hypertension, diabetes, smoking habit, cardiac disorders, cancer
and chronic neurological disorders were associated with higher
odds of mortality, whereas female sex was associated with a
lower odd of death. In the multivariate regression analysis,
including all the variables that were statistically significant in
the univariate analysis, baseline disability, age and chronic
neurological disorders remained statistically significant (OR:
1.76, 95% CI: 1.014–3.06). Table 2 presents the results of the
univariate and multivariate regression analysis.
Cox regression analysis patients with CND had lower survival
over time than patients without prior history of CND (HR:
2.13, 95% CI: 1.382–3.280, p = 0.001), adjusted by all the
variables included in the multivariate regression analysis (age,
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FIGURE 1 | Time between the first symptom and the emergency department (ED) visit in days. Y axis: Percentage of patients. X axis: Days since the first symptom to
the ED presentation.
TABLE 2 | Predictors of mortality: univariate and multivariate regression analysis.
Type of analysis OR 95% CI p-value
mRS≥3 Univariate 11.371 6.376–20.278 <0.001
Multivariate 4.100 2.088–8.050 <0.001
Age Univariate 1.090 1.069–1.112 <0.001
Multivariate 1.064 1.040–1.089 <0.001
Female sex Univariate 0.682 0.454–1.024 0.065
Multivariate 0.770 0373–1.052 0.077
Hypertension Univariate 3.534 2.272–5.495 <0.001
Multivariate 1.369 0.806–2.325 0.246
Diabetes Univariate 2.129 1.353–3.351 0.001
Multivariate 1.221 0.710–2.098 0.471
Smoking Univariate 1.589 1.004–2.514 0.048
Multivariate 1.720 0.955–3.096 0.701
Cardiological disorders Univariate 2.955 1.950–4.478 <0.001
Multivariate 1.208 0.730-1.999 0.462
Pulmonary disorders Univariate 1.434 0.928–2.217 0.105
Multivariate 0.931 0.543–1.596 0.794
Cancer Univariate 1.641 1.001–2.690 0.049
Multivariate 1.209 0.676–2.162 0.523
Chronic neurological disorders Univariate 3.961 2.516–6.234 <0.001
Multivariate 1.763 1.014–3.064 0.044
Immunosuppression Univariate 1.295 0.405–4.138 0.663
mRS, Modified Rankin Scale; OR, Odds Ratio; CI, Confidence Interval.
mRS, sex, presence of hypertension, diabetes, smoking habit,
prior history of cardiac disorders, pulmonary diseases, and
history of cancer). Figure 2 shows cumulative survival curves.
Supplementary Table 5 presents the results of all the variables
included in the analysis.
Predictors of Severe Covid-19 Disease
All the variables that were associated with higher odds of
mortality except by cancer were associated with a higher odd
of severe Covid-19 disease in the univariate regression analysis.
In the multivariate analysis, only age, female sex and diabetes
remained statistically significant, with a trend to signification in
smoking habit (p = 0.066) and CND (p = 0.063). Table 3 shows
results of univariate and multivariate regression analysis.
Laboratory Findings
The median laboratory values on admission and the worst values
during hospitalization is available in Supplementary Table 6.
All the laboratory parameters were more frequently abnormal
during the hospitalization than upon admission (all p <
0.001), Supplementary Table 7. Patients with CND had higher
odds of having increased INR during hospitalization (OR:
1.85, 95% CI: 1.14–3.01) and higher odds of having increased
procalcitonin levels during hospitalization (OR: 1.845, 95%
CI: 1.08–3.15), after adjusting for age, mRS, sex, and prior
history of hypertension, diabetes, smoking habit and other
comorbidities. Supplementary Table 8 shows the full results of
the regression analysis.
DISCUSSION
Most of the Covid-19 management protocols coincide that
patients with comorbidities should be closely monitored
(7, 11), however specific recommendations for neurological
comorbidities are sparse. Frequency of CND comorbidities in
Covid-19 patients have not been considered in most of the
studies (8). To our knowledge, this is the first study that analyzes
the implication of CND presence. CND was an independent
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FIGURE 2 | Cumulative survival of patients with and without chronic neurological disorders. Kaplan Meier curves. Y axis: Cumulative survival. X axis: Days after the
symptoms onset.
TABLE 3 | Predictors of severe Covid-19 disease. Univariate and multivariate
regression analysis.
Type of analysis OR 95% CI p-value
mRS>2 Univariate 2.437 1.241–4.786 0.010
Multivariate 1.272 0.587–2.756 0.542
Age Univariate 1.031 1.019–1.044 <0.001
Multivariate 1.029 1.013–1.045 <0.001
Female sex Univariate 0.584 0.410–0.832 0.003
Multivariate 0.642 0.437–0.942 0.024
Hypertension Univariate 1.485 1.044–2.113 0.028
Multivariate 0.802 0.522–1.232 0.314
Diabetes Univariate 2.714 1.600–4.603 <0.001
Multivariate 2.200 1.256–3.855 0.006
Smoking Univariate 2.083 1.279–3.392 0.003
Multivariate 1.648 0.967–2.809 0.066
Cardiological disorders Univariate 1.527 1.008–2.314 0.046
Multivariate 0.834 0.516–1.350 0.460
Pulmonary disorders Univariate 1.812 1.172-2.801 0.008
Multivariate 1.399 0.874–2.240 0.162
Cancer Univariate 1.534 0.924-2.547 0.098
Multivariate 1.182 0.689–2.027 0.523
Chronic neurological disorders Univariate 2.418 1.421–4.115 0.001
Multivariate 1.750 0.970–3.158 0.063
Immunosuppression Univariate 1.289 0.405–4.103 0.668
ADRS, Acute Distress Respiratory Syndrome; mRS, Modified Rankin Scale; OR, Odds
Ratio; CI, Confidence Interval.
predictor of in-hospital mortality, and death occurred faster in
CND patients.
As expected, patients with CND were older, more disabled
and had higher frequency of vascular risk factors and other
comorbidities. All of those have been associated with higher
mortality in most of the Covid-19 series (1–6). The clinical
presentation of Covid-19 disease was pauci symptomatic in CND
patients, as some typical symptoms such as cough, chest pain or
asthenia were less frequent. Also, the most frequently reported
neurological symptoms,myalgia, and headache (17–19), were less
common. Despite of that, CND patients experienced ADRSmore
often and had a higher death rate.
Considering the more severe disease, the worst baseline
performance and the scanty clinical expression, the reason for
the different outcome could be related with a delayed ED
presentation. However, in our sample, patients with CND came
earlier, even after adjusting for age, mRs, sex, and the rest of
comorbidities. Hence, we could not attribute the worse prognosis
to the delay in the care provision (6).
Then, we tried to find out if patients with CND received
standard care and/or intensive care less often. More than 80% of
CND patients received pharmacological treatment according to
the local SOC. Even though the clinical benefit of those drugs is
not yet clear (20), we could not attribute the worse prognosis to
the restriction of the received therapy. Due to the collapse of the
sanitary system, ICU guidelines deemed to prioritize the resource
allocation to those patients with a higher potential benefit (21).
Nevertheless, in our sample, patients with CND benefited from
ICU admission as frequently as those without it.
Since the need of oxygen therapy was more frequent in
patients with CND, a possible explanation of the higher mortality
was the more severe Covid-19 disease. As the simple comparison
ofmean ormedian values of laboratory findings was not adequate
due to the imbalanced populations, we analyzed if patients with
CND had abnormal laboratory values more frequently than the
rest of the patients, adjusting by all the variables that deemed
potential confounders. Only increased INR and procalcitonin
remained statistically significant. The reason why INR is more
frequently increased in patients with CND is elusive and could be
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related with hepatic failure caused by sepsis, low K vitamin levels,
or acute liver failure (22). In the case of procalcitonin, patients
with CND are more vulnerable to nosocomial infections (23), so
the bacterial co-infection could be the most likely explanation
(24, 25). It has been pointed as an independent predictor of fatal
outcome in Covid-19 patients (26).
Henceforth, if we could not attribute the worse prognosis
of CND patients neither to a delayed presentation to the ED
nor a different management (27), a plausible explanation could
be the higher fragility and lower reserve of CND population.
It is well-known that CND are independent predictors of
mortality in hospitalized patients (28, 29). Prior history of
stroke has been related with a higher odds of severe Covid-19
illness, as well (30). The possible reasons seem varied, including
frequency of delirium (18, 19), malnutrition (31), impaired
respiratory function (32), andworse self-management (33).Many
of them can be worsened by Covid-19 disease and the use of
personal protective equipment makes its management arduous.
Covid-19 should be prevented and detected early in CND
patients, whose close monitoring could prevent complications
and improve the prognosis (34). In addition, the worse prognosis
of patients with CND could be linked with immuno-senescence,
an enhanced inflammatory state, favored by an angiotensin II
induced vasoconstriction and inflammatory response, leading to
lymphopenia, cytokine release and macrophage activation (35).
This study has notable limitations. First, the sample size was
modest, implying the possibility of some false-negative results.
The number of CND was not high enough to perform sub-
studies by different specific conditions, but all the patients
were consecutive. We tried to create an operative definition of
CND, based on the persistent impact on functionality, however
the definition is imperfect and not every neurological disorder
might be equally relevant. Further studies should focus on the
specific impact of the different neurological comorbidities and
analyze them separately. Second, this was a single center study,
it would be desirable to create multicentric studies to clarify the
impact of other variables, such as the type of hospital care and
the different management of patients. Future studies should be
multinational, as the reported adjusted mortality rates are highly
variable between the different countries. It is not yet known
if it could be attributed to genetic predisposition for severe
Covid-19 or different healthcare systems. This was a retrospective
study and despite the information was carefully reviewed, some
information could be incomplete. It was a limitation that there
were many different researchers involved in the study, albeit all
of them were neurologists and followed a pre-defined protocol.
We did not include long-term follow up of the patients, some
patients remained admitted at the time of data cutoff, mortality
might be underestimated in some cases. Also, the sample is
not representative of the whole population, as it only included
hospitalized patients, which could influence the results.
CONCLUSION
The presence of pre-existing chronic neurological disorders was
an independent predictor of mortality in hospitalized Covid-
19 patients.
Death occurred faster after admission in patients with CND,
and CND was associated with an earlier presentation at ED.
Presence of CND was not associated with a worse inflammatory
response or with differences in the level of care provided to
the patients.
The course of Covid-19 in patients with CND appears to
be faster and more aggressive, and therefore protocols should
consider these patients as a very high-risk population.
Future Covid-19 studies should consider the presence of CND
in the evaluation of risk of mortality.
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